Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have agreed to take part voluntarily and have signed a consent form showing they understand the study.
• People aged 2 to 75 years at the time of signing the consent form (both males and females). For those under 18, a legal guardian must also sign the consent form, and young people who are able to make decisions must sign alongside their guardian.
• People who have been diagnosed with B-cell lymphoma based on established medical guidelines.
• People whose lymphoma did not respond well to their first treatment, or whose disease came back within 12 months after first-line treatment — or people who have had at least two lines of treatment (one standard chemotherapy course and one further treatment attempt) that did not work.
• People whose prior treatment included a CD20-targeted antibody therapy (unless testing confirmed the tumour does not have CD20) and a chemotherapy type called anthracycline.
• People who also meet at least one of the following: they are not suitable for a stem cell transplant using their own cells, they have chosen not to have that transplant, or their disease came back after having that transplant.
• People whose lymphoma is confirmed to be active (either relapsed or not responding to treatment) at the time of screening.
• People whose tumour tissue tests positive for a protein called CD19, confirmed by a laboratory test (ideally tested within the past 6 months).
• People who have at least one area of lymphoma that can be measured on scans, based on standard response criteria.
• People with a general health and activity level rated between 0 and 3 on a standard scale used by doctors (confirm with trial site).
• People with adequate levels of certain blood cells before the trial begins — specifically, a lymphocyte count of at least 0.3×10⁹/L and a platelet count of at least 30×10⁹/L.
• People whose liver, kidney, heart, and lung function meet specific minimum thresholds set by the trial (confirm with trial site for exact values).
• Women who could become pregnant must have a negative pregnancy test within 7 days before receiving the treatment. All participants must agree to use effective contraception throughout the study and for at least 1 year after treatment ends.
• People with suitable veins for the blood collection procedure required by this trial, and no medical reasons preventing that procedure.
• People whose doctors estimate they are likely to live for at least 3 more months.

Who may not be able to join:

• People who currently have another cancer, unless that cancer has been in remission for more than 3 years or is a very early-stage, non-invasive type.
• People with certain active viral infections, including active hepatitis B, active hepatitis C, syphilis, or HIV.
• People with any bacterial, fungal, viral, or other infection that is not currently under control, as assessed by the treating doctor.
• People with significant current or past brain or nervous system conditions — such as epilepsy, stroke, dementia, or certain autoimmune conditions affecting the brain — that the doctor considers uncontrolled.
• People who have had a heart procedure (such as a stent) within the 12 months before signing the consent form, or who have moderate-to-severe heart failure, a recent heart attack, unstable chest pain, or other serious heart conditions. People whose heart's electrical activity or pumping function falls outside the required range at screening are also excluded.
• People with a condition where their immune system does not work properly from birth (primary immunodeficiency).
• People who have a known severe allergic reaction to any of the treatments used in this trial.
• People who have received a live vaccine within 6 weeks before the screening visit.
• People who are pregnant or currently breastfeeding.
• People with an active autoimmune disease.
• People who have taken part in another interventional clinical trial within 30 days before signing the consent form.
• People whom the treating doctor considers unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.